Vaxcyte Amends Credit Agreement with OrbiMed
Ticker: PCVX · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1649094
| Field | Detail |
|---|---|
| Company | Vaxcyte, Inc. (PCVX) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $6.026, $5.941, $6.00, $1,091,276.59 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt, credit-agreement
TL;DR
Vaxcyte just tweaked its loan terms with OrbiMed.
AI Summary
On November 15, 2024, Vaxcyte, Inc. entered into a Material Definitive Agreement, specifically a Second Amendment to its Second Amended and Restated Credit Agreement with OrbiMed Royalty & Credit Fund, L.P. This amendment modifies the existing credit facility, impacting the terms and conditions of Vaxcyte's debt obligations.
Why It Matters
This amendment to Vaxcyte's credit agreement with OrbiMed Royalty & Credit Fund, L.P. could affect the company's financial flexibility and debt management strategies.
Risk Assessment
Risk Level: medium — Amendments to credit agreements can signal changes in a company's financial health or its ability to meet debt covenants.
Key Players & Entities
- Vaxcyte, Inc. (company) — Registrant
- OrbiMed Royalty & Credit Fund, L.P. (company) — Lender
- November 15, 2024 (date) — Date of earliest event reported
FAQ
What specific changes were made to the credit agreement?
The filing indicates a 'Second Amendment to the Second Amended and Restated Credit Agreement' was entered into, but the specific details of the amendments are not provided in this summary.
Who is the other party to the credit agreement?
The other party to the credit agreement is OrbiMed Royalty & Credit Fund, L.P.
What is the date of the event reported?
The date of the earliest event reported is November 15, 2024.
What type of filing is this?
This is a Form 8-K, a Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Vaxcyte, Inc.'s principal executive office address?
Vaxcyte, Inc.'s principal executive offices are located at 825 Industrial Road, Suite 300, San Carlos, California, 94070.
Filing Stats: 1,496 words · 6 min read · ~5 pages · Grade level 13.9 · Accepted 2024-11-21 16:10:59
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PCVX The Nasdaq
- $6.026 — mises at an initial monthly rate of (i) $6.026 per RSF for each of Suite 100A and Suit
- $5.941 — of the initial term of the lease), (ii) $5.941 per RSF for each of Suite 200A and Suit
- $6.00 — e initial term of the lease), and (iii) $6.00 per RSF for each of the Additional Prem
- $1,091,276.59 — al Lease and the Assumed Lease totaling $1,091,276.59 in the form of letters of credit (the "
- $5.95 — Premises at an initial monthly rate of $5.95 per RSF, which amount shall increase to
- $6.1285 — per RSF, which amount shall increase to $6.1285 per RSF on the first day of the calenda
Filing Documents
- d847442d8k.htm (8-K) — 33KB
- 0001193125-24-263406.txt ( ) — 153KB
- pcvx-20241115.xsd (EX-101.SCH) — 3KB
- pcvx-20241115_lab.xml (EX-101.LAB) — 18KB
- pcvx-20241115_pre.xml (EX-101.PRE) — 11KB
- d847442d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VAXCYTE, INC. Date: November 21, 2024 By: /s/ Andrew Guggenhime Andrew Guggenhime President and Chief Financial Officer